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ABSTRACT
Introduction: The aim of the present study was
to use real-world data from Swedish
primary-care and national registries to
understand clinical outcomes in patients with
Type 2 diabetes (T2D) treated with liraglutide in
clinical practice, and to compare with data from
those treated with sitagliptin.
Methods: This was a non-interventional,
retrospective study conducted between
February 2014 and September 2014 using T2D
patient data from Swedish primary-care centers
and national healthcare registries. The primary
objective was to assess the effectiveness of
liraglutide in control of glycemia and body
weight in clinical practice (stage 1). The
secondary objective was to compare the
clinical effectiveness of liraglutide with
sitagliptin on glycemic control and body
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weight in clinical practice in a
propensity-score-matched population (stage 2).
Results: In stage 1 (n = 402), 39.4% of patients
treated with liraglutide achieved C1.0%
(10.9 mmol/mol) reduction in glycated
hemoglobin (HbA1c) after 180 days of
treatment and 54.9% achieved the target
HbA1c of \7.0% (53.0 mmol/mol). Moreover,
compared with baseline, 22.5% of patients
treated with liraglutide achieved both C1.0%
reduction in HbA1c and C3.0% reduction in
body weight. In stage 2, a significantly greater
proportion of patients receiving liraglutide
(n = 180) than sitagliptin (n = 208) achieved
C1.0% reduction in HbA1c [52.9% vs 33.5%,
respectively (P = 0.0002)]. Mean body-weight
loss was also significantly greater in patients
receiving liraglutide vs sitagliptin [-3.5 vs
-1.3 kg, respectively (P\0.0001)].
Conclusion: This study provides real-world
evidence from Sweden corroborating previous
clinical trials that demonstrate greater efficacy
of liraglutide over sitagliptin on glycemic
control and body-weight reduction in patients
with T2D.
Funding: Novo Nordisk A/S.
Trial registration: ClinicalTrials.gov identifier
NCT02077946.
Keywords: Liraglutide; Real-world evidence;
Sitagliptin; Sweden; Type 2 diabetes
INTRODUCTION
Good glycemic control is a cornerstone of
prevention of long-term diabetic
complications and reduces mortality in
patients with type 2 diabetes (T2D) [1–3].
Incretin-based therapies, such as glucagon-like
peptide-1 receptor agonists (GLP-1RAs) or
dipeptidyl peptidase-4 inhibitors (DPP-4is), are
based on the intestinal hormone GLP-1 and
lead to improved glycemic control and have a
beneficial weight effect in patients with T2D [4].
Liraglutide is a once-daily human GLP-1RA
approved in over 100 countries worldwide for
the treatment of adults with T2D by once-daily
subcutaneous administration [5]. In the
European Union (EU)/Sweden, liraglutide at
doses up to 1.8 mg is indicated (approved in
January 2010) for treatment of adults with T2D
to achieve glycemic control in combination
with oral glucose-lowering drugs when these,
together with diet and exercise, provide
inadequate glycemic control. In April 2014,
liraglutide in T2D was approved in EU/Sweden
for use in combination with basal insulin.
Sitagliptin, a DPP-4i approved for use in
Sweden in June 2007, both as monotherapy and
in combination with other oral glucose-lowering
drugs and insulin for the treatment of T2D, has
been shown to improve glycemic control in
patients with T2D in several clinical trials [6, 7].
Moreover, sitagliptin is currently the most
commonly prescribed DPP-4i in Sweden.
Data from clinical trials demonstrated that
liraglutide was superior to sitagliptin in terms of
reducing both glycated hemoglobin (HbA1c)
and body weight in patients with T2D [8, 9].
Randomized controlled trials (RCTs) are the
gold standard for evaluating efficacy and safety
of therapeutic interventions [10], but regulatory
agencies and payers worldwide require
assurance that RCT findings translate into
clinical benefits in the broader patient
populations of clinical practice. Healthcare
providers, moreover, increasingly look for
real-world clinical evidence that new therapies
provide better outcomes and/or greater value
than existing standards of care [11].
The primary objective of this study was to
assess the effectiveness of liraglutide in control
of glycemia and body weight in clinical practice
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in Sweden. The secondary objective was to
compare the effectiveness of liraglutide vs
sitagliptin on glycemic control and
body-weight reduction. To reduce the possible
confounding effect on comparison of the two
treatments by different baseline patient
characteristics, which naturally vary more in
observational studies than in randomized trials,
propensity score-matching (PSM) was applied.
METHODS
Study Design and Data Extraction
This non-interventional, retrospective study
was conducted between February 2014 and
September 2014 where data from patients with
T2D were collected from primary care centers
(PCCs) and national healthcare registries in
Sweden. Fifty-three PCCs were selected from a
large geographical area of Sweden, representing
*5–6% of the Swedish population. Data were
extracted from electronic medical records
(EMRs) held by PCCs using the Pygargus
Customised eXtraction Program, CXP 3.0
(Pygargus; Stockholm, Sweden), a validated
data-extraction tool [12]. Primary care medical
records including laboratory measurements
were linked with data from the national
patient registry, national prescription registry,
and national LISA (longitudinal integration
database for health insurance and labor market
studies) database kept at Statistics Sweden, for
2010–2013. Data on diabetes and comorbidities
were also collected from the EMRs from 1996
onwards if available for each patient.
Patients
Inclusion criteria comprised the following:
patients treated in primary care with a diagnosis
of diabetes (International Classification of
Diseases 10th edition codes; E10, E11, E13, E14)
and receiving treatment with liraglutide
[Anatomical Therapeutic Chemical (ATC)-code
A10BX07] or sitagliptin (ATC-code A10BH01)
who were judged to have T2D, age C18 years,
treatment with liraglutide or sitagliptin started
between January 2010 and December 2013 (date
of first prescription purchase = index date), a
minimum of 180 days’ history within the
database before their index date, and at least
one HbA1c and body-weight measurement after
180 days’ therapy (defined as 180 days -60/
?180 days, always choosing the observation
closest to 180 days). Exclusion criteria
comprised the following: current or previous
cancer; end-stage liver disease; end-stage renal
failure; history of gestational diabetes; or
previous GLP-1RA or DPP-4i use other than
described in the inclusion criteria.
Outcome Measures
Outcomes data were measured *180 days after
index date and compared with data at or before
index date (i.e. baseline, which was the period
of 90 days before index date and 6 days
thereafter, always choosing the observation
closest to index date). Similar endpoints were
used in both stages of the study (Table S1).
Information on prescribed doses of liraglutide
or sitagliptin was collected for all patients, and
adherence to prescribed therapy was calculated
for each patient and then summarized by
treatment group. Adherence to therapy during
the study period was determined using the
medication possession ratio (MPR) (adherence
threshold; C80%).
Statistical Analyses
A feasibility assessment was conducted at 10
PCCs to determine sample size for the present
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study. At least 750 patients prescribed
liraglutide were needed for 80% power to find
a statistically significant difference between
treatment groups at the 5% level in proportion
of patients achieving C1.0% reduction in
HbA1c (primary endpoint). The number of
patients required was based on observations
that 40% and 28% of patients receiving
liraglutide and sitagliptin, respectively,
reached the primary endpoint in the feasibility
study and only 44% had HbA1c measurements.
All statistical analyses were performed using
SAS statistical software, SAS version 9.3 (Cary,
NC, USA). Descriptive statistics were calculated
for all variables. In stage 1, changes during the
study period in the primary endpoint were
analyzed using a Chi squared test. Changes in
HbA1c and body weight were compared with
baseline using t tests for the overall population
and the outcome, e.g. change in HbA1c and body
weight were compared using ANCOVA models
with the baseline values of HbA1c and body
weight, respectively, as covariates to compensate
for the expected difference in these variables at
baseline. Other variables [e.g. low-density
lipoprotein (LDL)-cholesterol, high-density
lipoprotein (HDL)-cholesterol and triglycerides]
were also compared using an ANCOVA with
baseline value of the variable as covariate. The
predictors for achieving HbA1c \7.0% were
investigated using logistic regression.
In stage 2, propensity scores were first
calculated from 29 pre-defined variables
covering demography, general disease and
diabetes (with values calculated on or before
index date). The liraglutide group was then
matched with the sitagliptin group using
a ‘greedy’ five-digit-matching without
replacement and with best match retained at
each step. A pilot survey of the available data
from this study showed that liraglutide-treated
patients had higher baseline body weight, body
mass index (BMI), and HbA1c than
sitagliptin-treated patients. Therefore, these
variables were excluded from the PSM to avoid
selecting patients from the tails of the body
weight, BMI and HbA1c distributions. Instead
these variables were included as covariates. The
study results were expected to be confounded
by changes in insulin dose during the 180-day
treatment period. Therefore, patients were
excluded from the main analysis population if
the insulin dose had changed during this time.
These patients were included in a post hoc
analysis, whereby change in HbA1c and body
weight were investigated stratified by change in
insulin dose with the baseline variable as
covariates. In stage 2, treatment groups were
compared using Chi squared tests for
categorical variables and ANCOVAs for
continuous variables.
Four pre-planned sensitivity analyses were
undertaken to investigate the robustness
relating to the primary endpoint in stage 2. In
the analyses, variables were incorporated singly
into the matching process in a cumulative
approach (analysis #1); each variable was
added into the matching procedure and then
removed in turn until all variables had been
examined (analysis #2), and the propensity
scores were divided into quartiles after
matching (analysis #3). The final sensitivity
analysis was conducted for all patients
(analysis #4).
Compliance with Ethics Guidelines
The study was conducted in accordance with the
Declaration of Helsinki and the Guidelines for
Good Pharmacoepidemiology Practices. Study
approval was obtained from the Ethical Review
Board in Stockholm, Sweden, and approval for
access to EMRs from individual PCCs. National
data-protection regulations were observed
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throughout, but patient-informed consent was
not required due to the de-identified nature of
collected data. The study is registered at
ClinicalTrials.gov (NCT02077946).
RESULTS
Patient Disposition and Treatment
In total, data were extracted from EMRs for 3676
patients (Fig. 1). Of these, 1155 patients were
prescribed liraglutide (1.2 mg prescribed for
89% of patients) and 2521 were prescribed
sitagliptin (100 mg prescribed for 95% of
patients) (Figure S1). A total of 402 patients
prescribed liraglutide (88% of patients with
MPR C80%) were included in stage 1.
In the liraglutide group, mean insulin dose
for all patients treated with insulin before
(34.3% of patients) and after (30.3% of
patients) index date was 66 and 54 IU,
respectively (stage 1; n = 402). By comparison,
mean insulin dose for all patients treated with
insulin before (18.1% of patients) and after
(19.2% of patients) index date was 79 and 74 IU,
respectively, in the sitagliptin group (n = 657).
Approximately 87% of patients prescribed
liraglutide and 80% of patients prescribed
sitagliptin had a final HbA1c measurement
within 80 days of discontinuing their
respective treatment (Figure S2).
After PSM, there were 317 patients in each
treatment group. Stage 2, however, comprised
180 patients receiving liraglutide and 208
patients receiving sitagliptin [MPR C80%;
63.3% vs 52.9%, respectively (P = 0.038)] due
to the exclusion of patients with a change in
insulin dose after index date.
Fig. 1 Patient disposition. Asterisk Non-diabetes-related.
Data are number of patients (% of total who had data
extracted for respective treatment) DPP-4i dipeptidyl
peptidase-4 inhibitor, GLP-1RA glucagon-like peptide-1
receptor agonist, HbA1c glycated hemoglobin, PSM
propensity score matching
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Patient Characteristics at Index Date
Before PSM and using sitagliptin as a reference,
patients treated with liraglutide received their
first diabetes diagnosis at a younger age, were
younger, heavier, and had a higher BMI
(Table 1). Furthermore, liraglutide-treated
patients had a greater disease severity, as
evidenced by a higher baseline HbA1c and a
greater number of prescriptions of insulin
in the 2 years before index date. Sitagliptin-
treated patients were often sulfonylurea (SU)
users before index date [mean (standard
deviation) prescriptions/patient/year 0.9 ± 1.8
Table 1 Patient characteristics at index date










At diagnosis 50.7 (9.0) 55.6 (11.0)d 51.8 (9.3) 51.4 (10.0)
At index date 58.6 (10.1) 62.6 (11.2)d 58.2 (9.7) 58.0 (11.2)
Time between diagnosis and
index date (years)
7.9 (4.4) 6.9 (4.1)c 6.4 (4.1) 6.6 (3.9)
Females, n (%) 142 (35.3) 218 (33.2) 60 (33.3) 81 (38.9)
Use of insulin within the
previous 2 years, n (%)
221 (55.0) 171 (26.0)d 22 (12.2) 27 (13.0)
Body-weight (kg) 106.7 (20.4) 96.4 (20.2)d [106.3 (20.0)] [97.4 (21.3)]c
BMI (kg/m2) 34.8 (5.6) 32.8 (6.5)d [34.9 (5.6)] [32.8 (6.5)]b
HbA1c (%) 7.8 (1.4) 7.5 (1.5)b [7.7 (1.4)] [7.5 (1.5)]
HbA1c (mmol/mol) 61.7 (15.3) 58.5 (16.4) [60.7 (15.3)] [58.5 (16.4)]
LDL-cholesterol (mmol/L) 2.6 (0.8) 2.6 (0.8) 2.6 (0.8) 2.7 (0.9)
HDL-cholesterol (mmol/L) 1.1 (0.4) 1.2 (0.4)a 1.1 (0.5) 1.2 (0.3)
Total cholesterol (mmol/L) 4.7 (1.2) 4.7 (1.1) 4.7 (1.1) 4.8 (1.1)
Triglycerides (mmol/L) 2.3 (1.4) 2.5 (2.6) 2.3 (1.4) 2.5 (2.6)
Creatinine (mmol/L) 75.1 (25.3) 77.8 (24.9) 72.5 (20.7) 72.3 (18.3)
SBP (mmHg) 136.8 (14.8) 135.2 (14.3) 136.4 (14.9) 134.9 (14.3)
DBP (mmHg) 78.6 (10.2) 78.0 (9.5) 79.4 (9.9) 79.3 (10.4)
Data are mean (SD) unless stated otherwise. [Body-weight, BMI and HbA1c were not included in the PSM as explained in
the ‘‘Statistical analysis’’ section. Therefore, post-PSM, both body-weight and BMI remained signiﬁcantly different between
the treatment groups. However, post-PSM, HbA1c was no longer signiﬁcantly different.] The n value relates to the number
of patients; the % value relates to the proportion of the total liraglutide/sitagliptin population
BMI body-mass index, DBP diastolic blood pressure, HbA1c glycated hemoglobin, HDL high-density lipoprotein, LDL
low-density lipoprotein, PSM propensity score matching, SBP systolic blood pressure, SD standard deviation
a P\0.05, b P\0.01, c P\0.001, d P\0.0001 vs liraglutide group
Analyses conducted on Aliraglutide group only or Bboth groups. CAnd excluding patients with changes in insulin dose
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in liraglutide-treated patients vs 1.3 ± 3.2
for sitagliptin-treated patients, P = 0.012]
(Table S2). After PSM, body weight and BMI
(not included in the matching) remained
significantly different between the groups. No
other parameters differed between the groups at
index date after PSM.
Clinical Effectiveness of Liraglutide
(Stage 1)
In total, 39.4% of the 402 patients treated with
liraglutide achieved C1.0% (C10.9 mmol/mol)
reduction in HbA1c after 180 days’ treatment
(primary endpoint) and 54.9% achieved the
HbA1c target of \7.0% [\53.0 mmol/mol
(Table 2)]. Baseline HbA1c was the only
predictor of achieving an end-of-study HbA1c
value \7.0% (\53.0 mmol/mol) that was
statistically significant (P\0.0001). HbA1c and
body weight were significantly reduced from
baseline after 180 days’ treatment with
liraglutide and 22.5% of patients treated with
liraglutide achieved the composite endpoint
based on the National Institute for Health and
Care Excellence (NICE) guidelines for liraglutide
treatment, i.e. both a reduction of C1.0%
(C10.9 mmol/mol) in HbA1c and C3.0% of
initial body weight (Table 2) [13]. Subgroup
analyses showed larger decreases in HbA1c for
patients with a higher vs lower baseline HbA1c
(P\0.0001), shorter vs longer duration of
diabetes before index date (P = 0.0384), and
with a less vs more intensive glucose-lowering
treatment before index date (based on several
subgroup analyses, all with P\0.0497). There
were no statistically significant associations
between change in HbA1c and baseline body
weight or BMI categories (P = 0.1058 and
P = 0.9368, respectively). A statistically
significant reduction in total cholesterol and
systolic blood pressure (BP) after 180 days’
treatment with liraglutide were found
(Table 2). However, no significant effects were
observed on LDL-cholesterol, HDL-cholesterol,
triglycerides, creatinine or diastolic BP
(Table 2).
Table 2 Clinical effectiveness of liraglutide after 180 days




Number (%) of patients achieving:
HbA1c reduction C1.0%
(10.9 mmol/mol) (primary endpoint)
145 (39.4)
HbA1c target\7.0% (53.0 mmol/mol) 221 (54.9)
Patients achieving a reduction C1.0% in
HbA1c and C3.0% of initial body-weight
(NICE)
73 (22.5)
Change from baseline in
HbA1c (%) -0.8 (1.4)b
HbA1c (mmol/mol) -8.5 (15.5)b
Body-weight (kg) -3.8 (4.2)b
LDL-cholesterol (mmol/L) -0.1 (0.7)
HDL-cholesterol (mmol/L) 0.0 (0.1)
Total cholesterol (mmol/L) -0.2 (1.0)a
Triglycerides (mmol/L) 0.0 (1.2)
Creatinine (mmol/L) 1.3 (14.3)
Systolic blood pressure (mmHg) -3.9 (16.1)b
Diastolic blood pressure (mmHg) -0.7 (10.7)
Includes patients receiving liraglutide with changes in
insulin dose. Data are mean (SD) unless stated otherwise.
The % value relates to the proportion of the liraglutide
population with data for that particular variable (not the
proportion of the total liraglutide population)
BMI body-mass index, HbA1c glycated hemoglobin, HDL
high-density lipoprotein, LDL low-density lipoprotein,
NICE National Institute for Health and Care Excellence,
n number of patients, SD standard deviation
a P\0.05, b P\0.0001 vs baseline value
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Effectiveness of Liraglutide vs Sitagliptin
(Stage 2)
After 180 days’ treatment, 52.9% of patients
receiving liraglutide achieved C1.0%
(C10.9 mmol/mol) reduction in HbA1c vs
33.5% of patients treated with sitagliptin
(P = 0.0002) (Fig. 2). Results from three of the
pre-specified sensitivity analyses showed similar
results. In sensitivity analysis #3, where the
population was divided into quartiles based on
the propensity score value, only the highest
quartile demonstrated significance. Patients in
this quartile are characterized by being older
and using less insulin.
In total, 71.1% of patients receiving liraglutide
achieved the HbA1c target of \7.0%
(\53.0 mmol/mol) compared with 63.5%
receiving sitagliptin (P = 0.1105). Stratifying
this analysis based on baseline HbA1c (post hoc
analysis) demonstrated that in patients who had
a baseline HbA1c C7.0% (C53.0 mmol/mol),
optimal glycemic control [HbA1c \7.0%
(\53.0 mmol/mol)] at study-end was achieved
by 39.4% of patients treated with liraglutide and
24.5% of patients treated with sitagliptin. The
post hoc analysis demonstrated that there was a
higher proportion of patients treated with
sitagliptin (6.0%) that increased their baseline
HbA1c from\7.0% (\53.0 mmol/mol) to C7.0%
(C53.0 mmol/mol) at study-end compared with
patients treated with liraglutide (1.5%). These
findings are despite approximately one-third of
patients in each group having both a baseline
and study-end HbA1c\7.0% (\53.0 mmol/mol),
(liraglutide, 32.6%; sitagliptin, 36.5%). There
were significantly greater HbA1c and
body-weight reductions in patients receiving
liraglutide compared with sitagliptin [HbA1c:
-1.2% (-13.1 mmol/mol) vs –0.7%
(-7.7 mmol/mol); body-weight: -3.5 vs
-1.4 kg, respectively] (Fig. 3). Consequently, a
significantly greater proportion of the liraglutide
group than the sitagliptin group achieved C3.0%
reduction in baseline body weight (51.6% vs
26.0%, respectively) and the composite endpoint
based on NICE guidelines for liraglutide
Fig. 2 Patients achieving the primary endpoint (C1.0%
reduction in HbA1c), a reduction of C3.0% of initial
body-weight, and fulﬁlling NICE criteria (for GLP-1RA
treatment) (composite endpoint—a reduction C1.0% in
HbA1c and C3.0% of initial body-weight) after 180 days
of treatment. Data are for cohorts after PSM and after the
exclusion of patients with a change in insulin dose during
the treatment period. Proportions are calculated from
patients with available data. GLP-1RA glucagon-like
peptide-1 receptor agonist, HbA1c glycated hemoglobin,
n number of patients, NICE National Institute for Health
and Care Excellence, PSM propensity score matching
Fig. 3 Mean changes in HbA1c and body weight after
180 days of treatment. Data are for cohorts after PSM and
after the exclusion of patients with a change in insulin dose
during the treatment period. Mean values are calculated
from patients with available data. HbA1c glycated
hemoglobin, n number of patients, PSM propensity score
matching
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treatment (27.0% vs 9.6%, respectively) (Fig. 2)
[13]. No statistically significant difference
between the groups was found for change from
baseline in LDL-cholesterol, HDL-cholesterol,
total cholesterol, BP (systolic and diastolic), and
creatinine. There was, however, a significantly
greater reduction in triglycerides observed with
patients treated with sitagliptin vs liraglutide
[-0.5 vs-0.1 mmol/L, respectively (P = 0.0093)].
Post hoc Analysis Including Patients
with Changes in Insulin Dose
After PSM, there were 317 patients in each
treatment group. Of the 137 (43.2%) patients
excluded from stage 2 analysis in the liraglutide
group due to changes in insulin dose, 101
(73.7%) had a mean reduction in insulin dose
of -33 IU (-25.4%) and 36 (26.3%) had a mean
increase of 30 IU (23.1%). Of the 109 (34.4%)
patients excluded in the sitagliptin group, 56
(51.4%) had a mean reduction in insulin dose of
31 IU (-23.0%), and 53 (48.6%) had a mean
increase of 32 IU (23.8%).
Of those patients that had a decrease in
insulin dose, mean reductions in HbA1c at the
end of treatment were -0.23% (-2.5 mmol/mol)
vs -0.27% (-3.0 mmol/mol) in the liraglutide
and sitagliptin groups, respectively (P = 0.5889).
Of those that had an increase in insulin dose,
mean reductions in HbA1c at the end of
treatment were -1.19% (-13.0 mmol/mol) vs
-0.69% (-7.5 mmol/mol) in the liraglutide and
sitagliptin groups, respectively (P = 0.1324). Of
those patients that had a decrease in insulin dose,
mean reductions in body weight at the end of
treatment were -4.5 vs -1.8 kg in the liraglutide
and sitagliptin groups, respectively (P = 0.0173).
Of those that had an increase in insulin dose,
mean changes in body weight at the end of
treatment were -1.1 vs 0.4 kg in the liraglutide
and sitagliptin groups, respectively (P = 0.0446).
DISCUSSION
In the current study, more than one-third of
patients treated with liraglutide achieved the
goal of C1.0% (C10.9 mmol/mol) reduction in
HbA1c. Furthermore, over half of patients
receiving liraglutide achieved the HbA1c target
of \7.0% (\53.0 mmol/mol) and there were
greater reductions in HbA1c and body weight in
patients receiving liraglutide than in those
receiving sitagliptin.
Using a retrospective cohort study design
allowed for collection and analysis of readily
available data from EMRs, and the application
of PSM limits the effects of confounding
inherent in the design. The results from this
study may be considered representative of the
national profile of patients with T2D in Sweden,
in part due to availability of data up to as
recently as May 2014 and the multicenter
design. However, due to the procedure of PSM
and the observational nature of this study,
selection bias cannot be excluded.
Additionally, the lack of safety/tolerability
evaluation is a limitation of the study as it
does not provide a full overview of the benefit/
risk profile of the drugs.
In the present study, a similar proportion of
the liraglutide group and the sitagliptin group
were excluded. However, there was a noticeable
difference between treatment groups in the
proportion of patients previously treated with
GLP-1RAs and DPP-4is (higher in the sitagliptin
group). This finding may, in part, be explained
by the higher age of the patients receiving
sitagliptin and the fact that more patients were
on insulin before index date in the liraglutide
group, pointing toward a more severe disease
cause in patients treated with liraglutide.
As intended for observational studies, the
inclusion and exclusion criteria used in the
current study were not as strict as those of
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clinical trials. Therefore, the normal clinical
practice and the prescribing habits of physicians
in Sweden could be investigated. Results
generated before applying PSM demonstrated
that clinicians in Sweden elect to prescribe
liraglutide to patients with T2D who are
younger and heavier with a greater disease
severity. This is comparable with recent
findings from a retrospective study from the
UK [14]. In the current study, patients in the
liraglutide group had a higher mean baseline
body weight than those in the sitagliptin group.
Therefore, physicians appear not to select SUs
for patients in the liraglutide group to prevent
further weight gain, which is a known
side-effect with SU treatment [15]. After
performing PSM, 137 and 109 patients in the
liraglutide and sitagliptin groups, respectively,
were excluded from the study because of
potential confounding caused by changes in
insulin dose within the 180 days’ observational
period. Before April 2014, use of liraglutide in
combination with basal insulin was considered
‘off-label’; however, the fact that such a high
proportion of patients were receiving liraglutide
with basal insulin at that time may indicate that
many physicians in Sweden were seeking better
glycemic control for this group of patients.
Recently, an RCT showed beneficial effects of
liraglutide in patients with T2D treated with
multiple daily insulin injections [16]. Data from
the post hoc analysis of the current study
demonstrated that when physicians in Sweden
added liraglutide to basal insulin, they tended
to reduce the insulin dose. As the use of basal
insulin with liraglutide was considered
‘off-label’ at this time, it is possible that many
physicians reduced the insulin dose more than
was necessary due to safety concerns. Also
noteworthy in the study, the likelihood that a
patient adhered to the treatment during
follow-up was higher with the liraglutide
regimen than with sitagliptin, as demonstrated
by the greater proportion of patients with an
MPR C80% in the liraglutide PSM population.
This latter finding may reflect greater treatment
satisfaction and/or better glycemic control in
patients receiving liraglutide than those
receiving sitagliptin [17].
In stage 1, the proportion of patients
achieving a C1.0% (C10.9 mmol/mol)
reduction in HbA1c was comparable with a
former meta-analysis (47.0% [18] and real-world
(29.3% [14]) data. Furthermore, the mean
change in HbA1c from baseline after 180 days’
treatment reported with liraglutide in
the current study was similar to previous
findings from other real-world studies [-0.6%
(-6.5 mmol/mol) to -1.1% (-11.8 mmol/mol)]
[14, 19–22]. The association between greater
reductions in HbA1c in response to liraglutide
in patients with high baseline HbA1c, a short
diabetes duration, and less intensive
glucose-lowering treatment regimens reported
in the current study also are comparable with
previous findings [23–26]. However,
confounding caused by greater changes in
insulin dose in patients with a longer diabetes
duration may render the association with
HbA1c reduction difficult to interpret. Low
baseline HbA1c was identified as a predictor of
achieving glycemic control, which is consistent
with findings from a recent meta-analysis of 25
RCTs [18]. The mean change in body weight
from baseline after 180 days’ treatment reported
with liraglutide in the current study was similar
to previous findings from another real-world
study (-3.8 kg [14]) and a recent RCT (-4.5 kg
[27]).
In stage 2, the change in HbA1c from
baseline in response to liraglutide and
sitagliptin was evaluated using three different
approaches: HbA1c reduction of C1.0%
(C10.9 mmol/mol); absolute change in HbA1c;
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and end-of-study value of HbA1c \7.0%
(\53.0 mmol/mol). In all of these analyses,
results for liraglutide were significantly better
than those for sitagliptin. These results, and the
finding that body-weight reduction with
liraglutide was also greater than with
sitagliptin, are largely in agreement with
results obtained in earlier prospective RCTs [8,
9, 28] and retrospective studies [14, 29]. In stage
2, findings relating to the primary endpoint
were verified by three sensitivity analyses. The
non-significant findings with the fourth
sensitivity analysis may be due to the low
numbers of patients in each sub-population as
the patients receiving liraglutide in each
sub-population had a higher percentage of
patients with C1.0% (C10.9 mmol/mol)
reduction in HbA1c than those receiving
sitagliptin. The findings relating to
body-weight reduction were not unexpected as
sitagliptin is generally considered to be
body-weight neutral [30]. It should be noted
that baseline body weight and BMI were not
included in the PSM and although baseline
body weight was adjusted for in the analyses,
results related to body weight may be
interpreted with greater caution than those
related to HbA1c. There was a significantly
greater reduction in triglycerides in the
sitagliptin group compared to the liraglutide
group. These findings are in contrast to previous
studies which reported no difference in
triglyceride levels between the liraglutide
and sitagliptin groups at either 26 or 52 weeks
[8, 9].
CONCLUSION
This study provides real-world evidence that
glycemic control improves and body weight is
reduced after initiating liraglutide in patients
with T2D in primary care in Sweden. It further
demonstrates greater effectiveness of liraglutide
over sitagliptin on glycemic control and
body-weight reduction in clinical practice in
patients with T2D, corroborating findings in
previous head-to-head clinical trials.
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